Vivos Therapeutics (VVOS) AI Stock Analysis

• Market Cap: $21.76M
• Dividend Yield: N/A
• Average Volume (3M): 421.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: 2.65%
• EPS Growth: 70.21%
• Country: US
• Employees: 109
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.55
• Shares Outstanding: 7,504,807
• 10 Day Avg. Volume: 324,525
• 30 Day Avg. Volume: 421,860
• PEG Ratio: 0.02
• Price to Book (P/B): 2.71
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 1.65
• Enterprise Value/Revenue: 2.49
• Enterprise Value/Gross Profit: 4.46
• Enterprise Value/Ebitda: -2.67
• 1Y Price Target: $6.50
• Price Target Upside: 143.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: $2.50 ▼(-6.37% Downside)

Vivos Therapeutics faces significant financial and operational challenges, with negative profitability and cash flow issues being the most impactful factors. Technical analysis indicates bearish momentum, and valuation metrics are weak. Despite strategic initiatives and financing, the current outlook remains cautious.

Positive Factors

Strategic Acquisition

The acquisition of The Sleep Center of Nevada provides Vivos with direct access to a large patient base, enhancing revenue potential and aligning with the company's strategic pivot towards high patient volume centers.

Revenue Growth Potential

The deployment of Sleep Optimization Teams is expected to significantly boost revenue with high contribution margins, supporting long-term growth and profitability.

Financing Secured

Securing significant financing provides Vivos with the necessary capital to support strategic acquisitions and future growth initiatives, enhancing financial stability.

Negative Factors

Revenue Decline

A decline in revenue indicates challenges in maintaining sales momentum, which could impact the company's ability to achieve profitability and sustain growth.

Increased Operating Loss

Rising operating losses due to increased expenses from acquisitions and lower revenues can strain financial resources, affecting long-term financial health.

High Leverage Risks

High leverage poses risks to financial stability, potentially limiting the company's ability to invest in growth opportunities and manage economic downturns.

Vivos Therapeutics Business Overview & Revenue Model

Company Description

Vivos Therapeutics, Inc. (VVOS) is a medical device company focused on the development and commercialization of innovative solutions for the treatment of sleep-disordered breathing, particularly obstructive sleep apnea (OSA). The company operates in the healthcare sector, offering a range of products that utilize advanced technology to provide non-invasive therapies aimed at improving the quality of life for patients suffering from sleep-related issues. Vivos Therapeutics is known for its proprietary oral appliance therapy, which aims to address the underlying anatomical causes of sleep apnea rather than just its symptoms.

How the Company Makes Money

Vivos Therapeutics generates revenue primarily through the sale of its patented medical devices and treatment systems for sleep apnea. The company operates a direct-to-consumer model as well as a business-to-business model, partnering with dental and healthcare professionals to promote and distribute its products. Key revenue streams include the sale of its oral appliances, ongoing treatment subscriptions, and potential licensing agreements. Vivos also benefits from collaborations with healthcare providers and institutions that utilize its technology in patient care, contributing to recurring revenue through follow-up treatments and related services.

Vivos Therapeutics Financial Statement Overview

Summary

Vivos Therapeutics shows revenue growth but struggles with profitability and cash flow. The balance sheet indicates improved equity but high leverage risks. Overall, financial stability and sustainable growth remain challenges.

Income Statement

Vivos Therapeutics has shown some positive revenue growth, with a 8.9% increase in 2024 compared to 2023. However, the company continues to face challenges in achieving profitability, indicated by negative EBIT and EBITDA margins, and a net income of zero in 2024. The consistent negative net profit margin over the years highlights ongoing operational struggles.

Balance Sheet

The balance sheet reflects improving equity, with stockholders' equity rising to $7.95 million in 2024 from $0.41 million in 2023, suggesting strengthened financial stability. However, the debt-to-equity ratio is relatively high, indicating potential leverage risks. The equity ratio remains moderate, demonstrating a balanced asset structure, but further stability is needed.

Cash Flow

The cash flow statement reveals persistent negative free cash flow, with minimal improvement over the years. Operating cash flow remains negative, highlighting ongoing cash burn, although financing activities have supported liquidity. The company needs to focus on improving operational efficiency to enhance cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.39M	15.03M	13.80M	16.02M	16.89M	13.07M
Gross Profit	8.05M	9.02M	8.27M	10.02M	12.60M	10.41M
EBITDA	-13.43M	-10.55M	-16.68M	-24.36M	-19.54M	-11.24M
Net Income	-14.32M	-11.14M	-13.58M	-23.84M	-20.29M	-12.06M
Balance Sheet
Total Assets	26.03M	15.28M	10.73M	13.72M	33.69M	25.33M
Cash, Cash Equivalents and Short-Term Investments	4.40M	6.26M	1.64M	3.52M	24.03M	18.21M
Total Debt	11.58M	1.51M	2.00M	2.41M	1.63M	1.29M
Total Liabilities	21.45M	7.33M	10.32M	8.92M	8.15M	8.41M
Stockholders Equity	4.58M	7.95M	411.00K	4.80M	25.54M	16.92M
Cash Flow
Free Cash Flow	-15.14M	-13.26M	-12.75M	-20.51M	-18.13M	-5.80M
Operating Cash Flow	-14.42M	-12.69M	-11.95M	-19.59M	-15.73M	-5.68M
Investing Cash Flow	-6.38M	-568.00K	-853.00K	-924.00K	-2.61M	-120.25K
Financing Cash Flow	18.30M	17.88M	10.92M	0.00	24.17M	23.54M

Vivos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 2.67 is below the 20-day moving average (MA) of 3.08, below the 50-day MA of 3.65, and below the 200-day MA of 3.61, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 27.01 is Positive, neither overbought nor oversold. The STOCH value of 15.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.

Vivos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRIX	45 Neutral	$17.67M	―	-105.72%	―	0.09%	51.09%
VVOS	44 Neutral	$21.76M	―	-262.03%	―	2.65%	70.21%
CODX	44 Neutral	$16.65M	―	-63.40%	―	-91.14%	9.47%
ADGM	41 Neutral	$22.30M	―	―	―	15.00%	71.57%
COCH	40 Underperform	$24.05M	―	―	―	-26.49%	-91.23%

Vivos Therapeutics Corporate Events

Vivos Therapeutics’ Earnings Call: Strategic Transition and Growth

Vivos Therapeutics Navigates Transition with Strategic Investments

Vivos Therapeutics Shifts Strategy Amid Financial Challenges

Vivos Therapeutics, Inc. is a medical technology company specializing in proprietary oral appliances and therapeutic treatments for sleep disorders, particularly obstructive sleep apnea (OSA). The company operates in the healthcare sector and is known for its innovative, non-surgical solutions for maxillofacial abnormalities linked to breathing and sleep issues.

Vivos Therapeutics Delays Q2 2025 10-Q Filing

Vivos Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the recent acquisition of The Sleep Center of Nevada, which requires additional time for auditing and integration of financial statements. The company expects to file the report within the five-day extension period allowed by the SEC. Financially, Vivos anticipates a significant increase in general and administrative expenses, leading to a material rise in net loss for the quarter compared to the previous year, largely due to one-time acquisition costs. The company remains committed to compliance, with CFO Bradford Amman signing off on the notification.

The most recent analyst rating on (VVOS) stock is a Buy with a $6.60 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.